These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36112929)

  • 41. [CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].
    Zheng Y; Ma XB; Jiang J; Wang YP
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):156-60. PubMed ID: 22800477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China.
    Shen Z; Wang L; Zhang B; Li T; Li D; He C; Xue Y; Wang Y; Li B; Liu Q; Zhang H; Gu W; Wang F; Wang C; Shi Y; Ye J; Zhu T; Miao Y; Huang S; Sang W
    Front Oncol; 2021; 11():754180. PubMed ID: 34804942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
    Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma.
    Kim HY; Jang MA; Kim HJ; Kim SJ; Kim WS; Kim SH
    Blood Res; 2017 Sep; 52(3):193-199. PubMed ID: 29043234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
    Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
    Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
    Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
    Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
    Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
    J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
    Yang M; Niu X; Yang X; Sun Y; Su W; Zhang J; Wu Q; Wang Y; Zhang Q; Ji H
    Exp Biol Med (Maywood); 2023 Sep; 248(17):1469-1478. PubMed ID: 36847415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
    Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
    J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Expression of CD30 in Patients with Diffuse Large B-Cell Lymphoma and Clinical Significance].
    Qu Y; Lu XZ; Wang RX; Hei XF; Li J; Xiao BT; Jia ZX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):450-457. PubMed ID: 38660851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Expression and Clinical Significance of Exosome Component 4 in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma].
    Hong JQ; Huang QH; Huang ZY; Fan LP; Lin QY; Huang HB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1684-1689. PubMed ID: 38071046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma].
    Zhang Q; Zhang HY; Zhong FL; Zhang WL; Xu L; Feng J; Meng QX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):399-402. PubMed ID: 23628041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
    Li L; Zhang X; Zhang T; Song Z; Hu G; Li W; Li L; Qiu L; Qian Z; Zhou S; Liu X; Feng L; Pan Y; Zhai Q; Meng B; Ren X; Fu K; Wang P; Wang X; Zhang H
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e381-e389. PubMed ID: 29983382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.
    Murase T; Yamaguchi M; Suzuki R; Okamoto M; Sato Y; Tamaru J; Kojima M; Miura I; Mori N; Yoshino T; Nakamura S
    Blood; 2007 Jan; 109(2):478-85. PubMed ID: 16985183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.